DHG

Drug Profile

DHG

Alternative Names: depolymerised holothuria glycosaminoglycan

Latest Information Update: 13 Aug 2002

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Class Anticoagulants
  • Mechanism of Action Glycosaminoglycan stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Deep vein thrombosis; Disseminated intravascular coagulation

Most Recent Events

  • 16 Sep 1997 A preclinical study has been added to the Thromboses pharmacodynamic section
  • 21 Aug 1997 A study has been added to the Thromboses pharmacodynamics section
  • 20 Feb 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top